drugset / Trial / NCT01928225
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Phase 2
Completed
180 enrolled
University of Witwatersrand, South Africa
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors. This study will test whether giving the quadrivalent vaccine to women prior to surgical treatment of the cervical cancer precursor will improve outcomes. We hypothesize that pre-treatment HPV vaccine will result in a reduced occurrence or cervical cancer precursors in follow-up.
Timeline
- Start
- 2014-09-02
- Primary completion
- 2017-11-30
- Completion
- 2018-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil | Vaccine | — | — |